Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

FDA Brief: Cemiplimab-rwlc Accepted for Review in First-Line Combination Therapy for Advanced Lung Cancer

News

Potential Correlation Between Stage Shift and Survival Among Patients With NSCLC

News

ZENITH20 Trial: Poziotinib in NSCLC After Prior Therapies

Medical Literature

Case Study in Advanced Lung Cancer: EML4-NTRK Gene Fusion and ALK Inhibitor Resistance

News

Potential Correlation Between Stage Shift and Survival Among Patients With NSCLC

News

Global Study of Sequential Afatinib and Osimertinib in EGFR Mutation–Positive NSCLC

Medical Literature

Is Neoadjuvant PD-1 Inhibition Plus Chemotherapy of Benefit in Locally Advanced NSCLC?

C. Jillian Tsai, MD, PhD, on Using Stereotactic Body Radiotherapy to Reduce Oligoprogression in Advanced Lung Cancer

Silvia Novello, MD, PhD, on NSCLC Treatment Guided by Pharmacogenomics

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

View More

More

News

FDA Grants Approval to Atezolizumab for Adjuvant Treatment of NSCLC

FDA Brief: Novel EGFR Inhibitor Granted Breakthrough Therapy Designation in Lung Cancer

Anti-TIGIT Monoclonal Antibody Plus Pembrolizumab Focus of Phase II Study in NSCLC

Tumor Biopsy Analysis of Anticancer Vaccine–Treated Patients With Advanced NSCLC

FDA Brief: Bemcentinib Combination Given Fast Track Status for STK11-Altered Advanced Lung Cancer

Spectrum-Selective Tyrosine Kinase Inhibitor Plus Nivolumab Under Study in NSCLC

ZENITH20 Trial: Poziotinib in NSCLC After Prior Therapies

ESMO 2021: Anticancer Vaccine Under Study in HLA-A2–Positive Lung Cancer

View More

Advertisement

Published

Medical Literature

Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

Can Supertype B44 HLA Antigen Shape Tumor Response in NSCLC?

Study Finds Ethnic Association With Oncogenic Mutations for Patients With Lung Carcinoma

View More

Ongoing

CE Activities

KRAS Mutations in NSCLC: Who, How, and When to Test

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer — Part 1 of a 4-Part Series

What’s on the Horizon for KRAS-Mutated NSCLC?

NCCN Pharmacy Updates: Updates on the Use of Immunotherapy & Targeted Therapy in NSCLC

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.